LONDON–(BUSINESS WIRE)–#GlobalHerpesTreatmentMarket–The herpes treatment market is poised to grow by USD 677.02 million during 2020-2024 progressing at a CAGR of almost 4% during the forecast period.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis
The report on the herpes treatment market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of herpes infection.
The herpes treatment market analysis includes the type segment and geography landscape. This study identifies the rising prevalence rate of shingles in the older population as one of the prime reasons driving the herpes treatment market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The Herpes Treatment Market covers the following areas:
Herpes Treatment Market Sizing
Herpes Treatment Market Forecast
Herpes Treatment Market Analysis
Companies Mentioned
- Bausch Health Companies Inc.
- Cipla Inc.
- Eli Lilly and Co.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Maruho Co. Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis AG
-
Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
Executive Summary
Market Landscape
- Market ecosystem
- Market characteristics
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Herpes zoster – Market size and forecast 2019-2024
- Herpes simplex – Market size and forecast 2019-2024
- Market opportunity by Type
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2019-2024
- Europe – Market size and forecast 2019-2024
- Asia – Market size and forecast 2019-2024
- ROW – Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive Scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bausch Health Companies Inc.
- Cipla Inc.
- Eli Lilly and Co.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Maruho Co. Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
-
List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/